Core Biomedicine Inc. has completed a $21 million series A financing and been awarded a Japan Agency for Medical Research and Development (AMED) grant to advance its lead programs through discovery and early clinical development.
The U.K. is setting up a nationwide registry of people with dementia, who will be pre-screened and consented, to speed up recruitment to clinical trials and collect real-world evidence of effectiveness once therapies are approved.
The Global Health Innovative Technology (GHIT) Fund is investing approximately ¥2.86 billion ($18 million) in six R&D projects for the development of drugs for malaria, tuberculosis (TB) and neglected tropical diseases.
The Global Health Innovative Technology (GHIT) Fund has invested in a number of R&D projects for the development of drugs for malaria, including a global partnership led by Medicines for Malaria Venture (MMV), Tanabe Pharma Corp. and the University of Georgia.
Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically significant results do not read across to clinical benefit for patients with Alzheimer’s disease.
Eisai Co. Ltd. has patented immunoconjugates comprising monoclonal antibodies targeting 5’-nucleotidase (CD73) covalently linked to cytotoxic drug. They are reported to be useful for the treatment of cancer.
A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc. presented clinical data at the Alzheimer's Association International Conference (AAIC) 2025 in Toronto, showing comparable efficacy and safety to the FDA-approved intravenous formulation.
Alzheon Inc.’s oral treatment for people in the early stages of Alzheimer’s disease missed its phase III primary endpoint, adding yet another therapy to a long list by many developers that can’t beat dementia. The study also received grant money, which is in increasingly short supply.
Antibody-drug conjugates (ADCs) have demonstrated their effectiveness in a variety of solid tumors such as breast, lung, ovarian or bladder cancer and in hematological cancers too. However, in some cancer types, like pancreatic cancer, treatment with ADCs needs enhancement through more appropriate targets and payloads.
